Autor: |
Yurdanur Sullu, Leman Tomak, Guzin Demirag, Bekir Kuru, Necati Ozen, Filiz Karagoz |
Jazyk: |
angličtina |
Rok vydání: |
2023 |
Předmět: |
|
Zdroj: |
Discover Oncology, Vol 14, Iss 1, Pp 1-11 (2023) |
Druh dokumentu: |
article |
ISSN: |
2730-6011 |
DOI: |
10.1007/s12672-023-00809-w |
Popis: |
Abstract Background Neoadjuvant chemotherapy (NAC) is widely used in the treatment of primary breast cancer. Different staging systems have been developed to evaluate the residual tumor after NAC and classify patients into different prognostic groups. Ki67, a proliferation marker, has been shown to be useful in predicting treatment response and prognosis. We aimed to investigate the prognostic importance Neo-Bioscore stage and pretreatment and posttreatment Ki67 levels in breast cancer patients who received NAC and correlations between Neo-Bioscore stage and pretreatment and posttreatment Ki67 levels. Methods A total of 176 invasive breast carcinoma patients who underwent NAC were included in the study. Ki67 levels were evaluated by immunohistochemical methods in Trucut biopsy and surgical excision specimens. Patients were classified into prognostic groups using the Neo-Bioscore staging system. Results Patients with high pretreatment Ki67 score were more likely to be in the higher Neo-Bioscore risk group (p |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|